12 results match your criteria Novel Antipsychotic Drugs[Journal]

  • Page 1 of 1

Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Drugs 2018 04;78(5):525-541

Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 7200 Cambridge, Suite 9A, Houston, TX, 77030, USA.

Tardive dyskinesia (TD) encompasses the spectrum of iatrogenic hyperkinetic movement disorders following exposure to dopamine receptor-blocking agents (DRBAs). Despite the advent of atypical or second- and third-generation antipsychotics with a presumably lower risk of complications, TD remains a persistent and challenging problem. Prevention is the first step in mitigating the risk of TD, but early recognition, gradual withdrawal of offending medications, and appropriate treatment are also critical. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-018-0874-xDOI Listing
April 2018
16 Reads

Brexpiprazole: First Global Approval.

Authors:
Sarah L Greig

Drugs 2015 Sep;75(14):1687-97

Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand.

Brexpiprazole (Rexulti®) is an atypical antipsychotic that has been developed by Otsuka Pharmaceutical Co. Ltd and H. Lundbeck A/S as an oral treatment for several psychiatric disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-015-0462-2DOI Listing
September 2015
35 Reads

Alternative delivery systems for agents to treat acute agitation: progress to date.

Drugs 2013 Nov;73(16):1783-92

Psychiatric Emergency Service, Denver Health Medical Center, 777 Bannock St, Denver, CO, 80204, USA,

Psychomotor agitation is often associated with aggression. It is important to identify agitation early and achieve results quickly in order to prevent aggressive behavior. Strategies may include verbal de-escalation techniques, reduced stimulation, medications, or a combination of approaches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-013-0130-3DOI Listing
November 2013
5 Reads

Risperidone long-acting injection: in bipolar I disorder.

Authors:
Emma D Deeks

Drugs 2010 May;70(8):1001-12

Adis, a Wolters Kluwer Business, Auckland, New Zealand.

A long-acting intramuscular formulation of the atypical antipsychotic agent risperidone is now indicated for the maintenance treatment of patients with bipolar I disorder. The formulation utilizes a novel drug delivery system of biodegradable microspheres and is bioequivalent to the oral formulation of the drug. Moreover, fluctuations in plasma drug concentrations at steady state were 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/11204480-000000000-00000DOI Listing
May 2010
6 Reads

Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.

Drugs 2003 ;63(5):493-512

Department of Psychiatry, Department of Clinical Sciences Luigi Sacco, University of Milan, Via G.B. Grassi 74, Milan 20157, Italy.

Intramuscular formulations of antipsychotics can be sub-divided into two groups on the basis of their pharmacokinetic features: short-acting preparations and long-acting or depot preparations. Short-acting intramuscular formulations are used to manage acute psychotic episodes. On the other hand, long-acting compounds, also called "depot", are administered as antipsychotic maintenance treatment to ensure compliance and to eliminate bioavailability problems related to absorption and first pass metabolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00003495-200363050-00004DOI Listing
June 2003
11 Reads

Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.

Drugs 2002 ;62(8):1217-51

Adis International Limited, Auckland, New Zealand.

Unlabelled: Ziprasidone is a novel antipsychotic agent with a pharmacological profile distinct from that of other currently available novel or classical antipsychotics. In preclinical studies, ziprasidone was predicted to have efficacy against positive, negative and affective symptoms of schizophrenia with a favourable tolerability profile, including a low propensity to induce extrapyramidal adverse effects. The drug has been administered orally to >300 patients with an acute exacerbation of schizophrenia or schizoaffective disorder in published 4- to 6-week randomised, double-blind trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00003495-200262080-00015DOI Listing
September 2002
8 Reads

Emerging options in the treatment of bipolar disorders.

Drugs 2001 ;61(10):1407-14

Department of Psychiatry, University of Melbourne, Geelong, Victoria, Australia.

Bipolar disorder is a common and severe condition, and has a clinical outcome that is frequently sub-optimal. Only a small number of therapeutic options are currently available for the disorder. A growing range of novel therapeutic options for the treatment of bipolar disorder are under investigation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00003495-200161100-00004DOI Listing
January 2002
4 Reads

Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes.

Drugs 1997 Jun;53(6):915-29

Innsbruck University Clinics, Department of Biological Psychiatry, Austria.

The current state of the art of the pharmacological treatment of schizophrenia, and a review of the latest findings in antipsychotic drug development are presented. A first step in optimising treatment is an increase in the awareness and implementation of existing treatment standards. The introduction of clozapine challenges the view that all antipsychotics are of similar efficacy; the drug has an established superiority over some of the traditional antipsychotics in treatment-resistant patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00003495-199753060-00002DOI Listing
June 1997
6 Reads

Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.

Authors:
M I Wilde A Markham

Drugs 1996 Nov;52(5):773-94

Adis International Limited, Auckland, New Zealand.

The use of ondansetron, a selective serotonin 5-HT3 receptor antagonist, is well established in patients with nausea and vomiting associated with cancer chemotherapy, radiotherapy or anaesthesia and surgery. The wide distribution of 5-HT3 receptors in the body and the role of these receptors in disease have provided the rationale for investigation of ondansetron in novel applications. Preliminary data have shown ondansetron to have clinical benefit in patients with nausea and vomiting associated with drug overdosage or poisoning, anti-infective or antidepressant therapies, uraemia or neurological trauma, and in patients with pruritus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00003495-199652050-00010DOI Listing
November 1996
5 Reads

Drug treatment of chemotherapy-induced delayed emesis.

Drugs 1996 Nov;52(5):639-48

Section of Medical Oncology, St Elizabeth's Medical Center, Boston, Massachusetts, USA.

Chemotherapy-induced emesis has a major adverse impact on patients undergoing therapy for various malignancies, and this has led to considerable research in this field. Most investigative efforts have concentrated on the acute phase of emesis that occurs within the first 24 hours after chemotherapy, and significant strides forward have been made with this problem. Better control of acute emesis with newer agents such as the serotonin 5-HT3 receptor antagonists has focused increasing attention on a second phase of nausea and vomiting, known as delayed emesis, which occurs more than 24 hours after chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00003495-199652050-00002DOI Listing
November 1996
5 Reads

Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia.

Authors:
S Grant A Fitton

Drugs 1994 Aug;48(2):253-73

Adis International Limited, Auckland, New Zealand.

Risperidone, a benzisoxazol derivative, is a novel antipsychotic agent which combines potent serotonin (5-hydroxytryptamine) 5-HT2 and dopamine D2 receptor antagonism. Development of the drug was stimulated by reports that the selective serotonin 5-HT2 antagonist ritanserin improved the negative symptoms of schizophrenia and decreased extrapyramidal symptoms when combined with haloperidol. The relatively low incidence of extrapyramidal symptoms with risperidone may reflect a preferential action on mesolimbic rather than nigrostriatal dopaminergic pathways. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00003495-199448020-00009DOI Listing
August 1994
4 Reads

Drug treatment of resistant schizophrenia. Limitations and recommendations.

Drugs 1993 Mar;45(3):374-83

Department of Psychological Medicine, University of Wales College of Medicine, Heath Park, Cardiff.

Despite the advances achieved since the introduction of chlorpromazine, schizophrenia may respond inadequately to standard drug treatments. The reasons for this include noncompliance, poor tolerance and the development of distressing side effects or the resistance of the illness itself. Treatment-resistant schizophrenia is increasingly the focus of new research developments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00003495-199345030-00006DOI Listing
March 1993
6 Reads
  • Page 1 of 1